Joshua J. Gagne

Joshua J. Gagne

Auto-generated profile, based on publicly available information

Joshua J. Gagne

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
SWShirley V. Wang
Shirley V. Wang
SSSebastian Schneeweiss
Sebastian Schneeweiss
MBMarc L. Berger
Marc L. Berger
JBJeffrey Brown
Jeffrey Brown
FVFrank de Vries
Frank de Vries
OMon behalf of the joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making
on behalf of the joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making
Purpose: Defining a study population and creating an analytic dataset from longitudinal healthcare databases involves many decisions. Our objective was to catalogue scientific decisions underpinning study execution that should be reported to facilitate replication and enable assessment of validity of studies conducted in large healthcare databases.Methods: We reviewed key investigator decisions required to operate a sample of macros and software tools designed to create and analyze analytic cohorts from longitudinal streams of healthcare data. A panel of academic, regulatory, and industry experts in healthcare database analytics discussed and added to this list.Conclusion: Evidence generated from large healthcare encounter and reimbursement databases is increasingly being sought by decision‐makers. Varied terminology is used around the world for the same concepts. Agreeing on terminology and which parameters from a large catalogue are the most essential to report for replicable research would improve transparency and facilitate assessment of validity. At a minimum, reporting for a database study should provide clarity regarding operational definitions for key temporal anchors and their relation to each other when creating the analytic dataset, accompanied by an attrition table and a design diagram.A substantial improvement in reproducibility, rigor and confidence in real world evidence generated from healthcare databases could be achieved with greater transparency about operational study parameters used to create analytic datasets from longitudinal healthcare databases.

1 September 2019 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
NKNazleen F. Khan
Nazleen F. Khan
BBBrian T. Bateman
Brian T. Bateman
JLJoan E. Landon
Joan E. Landon
JGJoshua J. Gagne
Joshua J. Gagne
The US Centers for Disease Control and Prevention estimated that opioid overdose was responsible for more than 42 000 deaths in the United States in 2016 alone.1 In that year, approximately 11.5 million people misused prescription opioid medications,2 and more than 2 million individuals misused prescription opioid medications for the first time.3 In October 2017, the US Department of Health and Human Services declared a public health emergency in response to the ongoing opioid epidemic.4 Data from state departments of health suggest that the rates of overdose mortality have continued to increase.5,6

13 March 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
Suzanne M. CadaretteSuzanne M. Cadarette
Suzanne M. Cadarette
MMMalcolm Maclure
Malcolm Maclure
JDJ. A. Chris Delaney
J. A. Chris Delaney
HWHeather J. Whitaker
Heather J. Whitaker
KHKaleen N. Hayes
Kaleen N. Hayes
JHJesper Hallas
Jesper Hallas
Purpose: Consensus is needed on conceptual foundations, terminology and relationships among the various self‐controlled “trigger” study designs that control for time‐invariant confounding factors and target the association between transient exposures (potential triggers) and abrupt outcomes. The International Society for Pharmacoepidemiology (ISPE) funded a working group of ISPE members to develop guidance material for the application and reporting of self‐controlled study designs, similar to Standards of Reporting Observational Epidemiology (STROBE). This first paper focuses on navigation between the types of self‐controlled designs to permit a foundational understanding with guiding principles.Methods: We leveraged a systematic review of applications of these designs, that we term Self‐controlled Crossover Observational PharmacoEpidemiologic (SCOPE) studies. Starting from first principles and using case examples, we reviewed outcome‐anchored (case‐crossover [CCO], case‐time control [CTC], case‐case‐time control [CCTC]) and exposure‐anchored (self‐controlled case‐series [SCCS]) study designs.Results: Key methodological features related to exposure, outcome and time‐related concerns were clarified, and a common language and worksheet to facilitate the design of SCOPE studies is introduced.Conclusions: Consensus on conceptual foundations, terminology and relationships among SCOPE designs will facilitate understanding and critical appraisal of published studies, as well as help in the design, analysis and review of new SCOPE studies. This manuscript is endorsed by ISPE.

1 November 2018 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Open access
HKHiraku Kumamaru
Hiraku Kumamaru
MLMoa P. Lee
Moa P. Lee
NCNiteesh K. Choudhry
Niteesh K. Choudhry
YDYaa-Hui Dong
Yaa-Hui Dong
AKAlexis A. Krumme
Alexis A. Krumme
JGJoshua J. Gagne
Joshua J. Gagne
Medication nonadherence is a major public health problem. Identification of patients who are likely to be and not be adherent can guide targeted interventions and improve the design of comparative-effectiveness studies. To evaluate multiple measures of patient previous medication adherence in light of predicting future statin adherence in a large U.S. administrative claims database. We identified a cohort of patients newly initiating statins and measured their previous adherence to other chronic preventive medications during a 365-day baseline period, using metrics such as proportion of days covered (PDC), lack of second fills, and number of dispensations. We measured adherence to statins during the year after initiation, defining high adherence as PDC ≥ 80%. We built logistic regression models from different combinations of baseline variables and previous adherence measures to predict high adherence in a random 50% sample and tested their discrimination using concordance statistics (c-statistics) in the other 50%. We also assessed the association between previous adherence and subsequent statin high adherence by fitting a modified Poisson model from all relevant covariates plus previous mean PDC categorized as < 25%, 25%-79%, and ≥ 80%. Among 89,490 statin initiators identified, a prediction model including only demographic variables had a c-statistic of 0.578 (95% CI = 0.573-0.584). A model combining information on patient comorbidities, health care services utilization, and medication use resulted in a c-statistic of 0.665 (95% CI = 0.659-0.670). Models with each of the previous medication adherence measures as the only explanatory variable yielded c-statistics ranging between 0.533 (95% CI = 0.529-0.537) for lack of second fill and 0.666 (95% CI = 0.661-0.671) for maximum PDC. Adding mean PDC to the combined model yielded a c-statistic of 0.695 (95% CI = 0.690-0.700). Given a sensitivity of 75%, the predictor improved the specificity from 47.7% to 53.6%. Patients with previous mean PDC < 25% were half as likely to show high adherence to statins compared with those with previous mean PDC ≥ 80% (risk ratio = 0.49, 95% CI = 0.46-0.50). Including measures of previous medication adherence yields better prediction of future statin adherence than usual baseline clinical measures that are typically used in claims-based studies. This study was funded by the Patient-Centered Outcomes Research Institute (ME-1309-06274). Kumamaru, Kohsaka, and Miyata are affiliated with the Department of Healthcare Quality Assessment at the University of Tokyo, which is a social collaboration department supported by National Clinical Database. The department was formerly supported by endowments from Johnson & Johnson K.K., Nipro, Teijin Pharma, Kaketsuken K.K., St. Jude Medical Japan, Novartis Pharma K.K., Taiho Pharmaceutical, W. L. Gore & Associates, Olympus Corporation, and Chugai Pharmaceutical. Gagne has received grants from Novartis Pharmaceuticals and Eli Lilly and Company to the Brigham and Women's Hospital for unrelated work. He is a consultant to Aetion, a software company, and to Optum. Choudhry has received grants from the National Heart, Lung, and Blood Institute, PhRMA Foundation, Merck, Sanofi, AstraZeneca, CVS, and MediSafe. Schneeweiss is consultant to WHISCON and Aetion, a software manufacturer of which he also owns equity. He is principal investigator of investigator-initiated grants to the Brigham and Women's Hospital from Bayer, Genentech, and Boehringer Ingelheim unrelated to the topic of this study. He does not receive personal fees from biopharmaceutical companies. No potential conflict of interest was reported by the other authors.

16 November 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
KBKatsiaryna Bykov
Katsiaryna Bykov
SSSebastian Schneeweiss
Sebastian Schneeweiss
Macarius M. DonneyongMacarius M. Donneyong
Macarius M. Donneyong
YDYaa-Hui Dong
Yaa-Hui Dong
NCNiteesh K. Choudhry
Niteesh K. Choudhry
JGJoshua J. Gagne
Joshua J. Gagne

22 January 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
YDY.‐H. Dong
Y.‐H. Dong
YJY. Jin
Y. Jin
TTT. N. Tsacogianis
T. N. Tsacogianis
MHM. He
M. He
PHP.‐H. Hsieh
P.‐H. Hsieh
JGJ. J. Gagne
J. J. Gagne